[ad_1]
AstraZeneca PLC said on Friday that Imfinzi – used to treat certain cancers – has been approved by the US Food and Drug Administration for less frequent fixed-dose use.
The British pharmacy giant said the new four-week dosage option gives doctors the choice to halve the number of visits for critical cancer treatment and offers a more convenient regimen for patients.
Imfinzi has been approved for a 1,500 milligram every four weeks dosage option for the approved indications of unresectable stage III non-small cell lung cancer following treatment with chemoradiotherapy and previously treated advanced bladder cancer.
The company said it also limited potential exposure to infection in the healthcare setting for a population particularly vulnerable to complications from Covid-19.
AstraZeneca added that the fixed dosage option is under regulatory review in several other countries, including the EU.
[ad_2]
Source link